Show simple item record

dc.contributor.authorvan Straalen, Joeri W.
dc.contributor.authorde Roock, Sytze
dc.contributor.authorGiancane, Gabriella
dc.contributor.authorConsolaro, Alessandro
dc.contributor.authorRygg, Marite
dc.contributor.authorNordal, Ellen Berit
dc.contributor.authorRubio-Pérez, Nadina
dc.contributor.authorJelusic, Marija
dc.contributor.authorDe Inocencio, Jaime
dc.contributor.authorVojinovic, Jelena
dc.contributor.authorWulffraat, Nico M.
dc.contributor.authorBruijning-Verhagen, Patricia C. J.
dc.contributor.authorRuperto, Nicolino
dc.contributor.authorSwart, Joost F.
dc.date.accessioned2022-12-22T08:47:31Z
dc.date.available2022-12-22T08:47:31Z
dc.date.created2022-12-05T13:50:50Z
dc.date.issued2022
dc.identifier.citationPediatric Rheumatology. 2022, 20 (1), .en_US
dc.identifier.issn1546-0096
dc.identifier.urihttps://hdl.handle.net/11250/3039171
dc.description.abstractBackground Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on patient-reported well-being in non-systemic JIA using real-world data. Methods Biological-naive patients without a history of uveitis were selected from the international Pharmachild registry. Patients starting ETN were matched to patients starting ADA based on propensity score and outcomes were collected at time of therapy initiation and 3–12 months afterwards. Primary outcome at follow-up was the improvement in Juvenile Arthritis Multidimensional Assessment Report (JAMAR) visual analogue scale (VAS) well-being score from baseline. Secondary outcomes at follow-up were decrease in active joint count, adverse events and uveitis events. Outcomes were analyzed using linear and logistic mixed effects models. Results Out of 158 eligible patients, 45 ETN starters and 45 ADA starters could be propensity score matched resulting in similar VAS well-being scores at baseline. At follow-up, the median improvement in VAS well-being was 2 (interquartile range (IQR): 0.0 – 4.0) and scores were significantly better (P = 0.01) for ETN starters (median 0.0, IQR: 0.0 – 1.0) compared to ADA starters (median 1.0, IQR: 0.0 – 3.5). The estimated mean difference in VAS well-being improvement from baseline for ETN versus ADA was 0.89 (95% CI: -0.01 – 1.78; P = 0.06). The estimated mean difference in active joint count decrease was -0.36 (95% CI: -1.02 – 0.30; P = 0.28) and odds ratio for adverse events was 0.48 (95% CI: 0.16 –1.44; P = 0.19). One uveitis event was observed in the ETN group. Conclusions Both ETN and ADA improve well-being in non-systemic JIA. Our data might indicate a trend towards a slightly stronger effect for ETN, but larger studies are needed to confirm this given the lack of statistical significance.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleReal-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort studyen_US
dc.title.alternativeReal-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume20en_US
dc.source.journalPediatric Rheumatologyen_US
dc.source.issue1en_US
dc.identifier.doi10.1186/s12969-022-00763-x
dc.identifier.cristin2088800
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal